NATCO Pharma バランスシートの健全性
財務の健全性 基準チェック /66
NATCO Pharmaの総株主資本は₹58.5B 、総負債は₹3.7Bで、負債比率は6.3%となります。総資産と総負債はそれぞれ₹69.1Bと₹10.5Bです。 NATCO Pharmaの EBIT は₹19.7Bで、利息カバレッジ比率97.5です。現金および短期投資は₹18.5Bです。
主要情報
6.3%
負債資本比率
₹3.71b
負債
| インタレスト・カバレッジ・レシオ | 97.5x |
| 現金 | ₹18.49b |
| エクイティ | ₹58.53b |
| 負債合計 | ₹10.53b |
| 総資産 | ₹69.06b |
財務の健全性に関する最新情報
NATCO Pharma (NSE:NATCOPHARM) Seems To Use Debt Rather Sparingly
Jun 30
Is NATCO Pharma (NSE:NATCOPHARM) A Risky Investment?
Jan 25Is NATCO Pharma (NSE:NATCOPHARM) A Risky Investment?
Jul 16Does NATCO Pharma (NSE:NATCOPHARM) Have A Healthy Balance Sheet?
Jun 23Recent updates
We Ran A Stock Scan For Earnings Growth And NATCO Pharma (NSE:NATCOPHARM) Passed With Ease
Oct 13NATCO Pharma Limited's (NSE:NATCOPHARM) Shares Bounce 26% But Its Business Still Trails The Market
Aug 13If EPS Growth Is Important To You, NATCO Pharma (NSE:NATCOPHARM) Presents An Opportunity
Jul 15NATCO Pharma (NSE:NATCOPHARM) Seems To Use Debt Rather Sparingly
Jun 30NATCO Pharma Limited's (NSE:NATCOPHARM) Earnings Are Not Doing Enough For Some Investors
Jun 14NATCO Pharma Limited (NSE:NATCOPHARM) Exceeded Expectations And The Analyst Consensus Has Been Reviewing Its Models
May 30Calculating The Fair Value Of NATCO Pharma Limited (NSE:NATCOPHARM)
May 09Does NATCO Pharma (NSE:NATCOPHARM) Deserve A Spot On Your Watchlist?
Apr 03NATCO Pharma (NSE:NATCOPHARM) Is Due To Pay A Dividend Of ₹1.25
Feb 21NATCO Pharma Limited Just Beat EPS By 223%: Here's What Analysts Think Will Happen Next
Feb 18NATCO Pharma Limited (NSE:NATCOPHARM) Surges 25% Yet Its Low P/E Is No Reason For Excitement
Feb 17Is NATCO Pharma (NSE:NATCOPHARM) A Risky Investment?
Jan 25An Intrinsic Calculation For NATCO Pharma Limited (NSE:NATCOPHARM) Suggests It's 37% Undervalued
Jan 09Does NATCO Pharma (NSE:NATCOPHARM) Deserve A Spot On Your Watchlist?
Dec 13An Intrinsic Calculation For NATCO Pharma Limited (NSE:NATCOPHARM) Suggests It's 42% Undervalued
Sep 30Here's Why We Think NATCO Pharma (NSE:NATCOPHARM) Might Deserve Your Attention Today
Sep 12NATCO Pharma (NSE:NATCOPHARM) Is Paying Out A Larger Dividend Than Last Year
Aug 12Is NATCO Pharma (NSE:NATCOPHARM) A Risky Investment?
Jul 16NATCO Pharma Limited (NSE:NATCOPHARM) Shares Could Be 44% Below Their Intrinsic Value Estimate
Apr 20Is NATCO Pharma Limited (NSE:NATCOPHARM) Trading At A 46% Discount?
Dec 20NATCO Pharma's (NSE:NATCOPHARM) Upcoming Dividend Will Be Larger Than Last Year's
Aug 12Does NATCO Pharma (NSE:NATCOPHARM) Have A Healthy Balance Sheet?
Jun 23Broker Revenue Forecasts For NATCO Pharma Limited (NSE:NATCOPHARM) Are Surging Higher
Jun 02財務状況分析
短期負債: NATCOPHARMの 短期資産 ( ₹40.2B ) が 短期負債 ( ₹9.7B ) を超えています。
長期負債: NATCOPHARMの短期資産 ( ₹40.2B ) が 長期負債 ( ₹804.0M ) を上回っています。
デット・ツー・エクイティの歴史と分析
負債レベル: NATCOPHARM総負債よりも多くの現金を保有しています。
負債の削減: NATCOPHARMの負債対資本比率は、過去 5 年間で11.1%から6.3%に減少しました。
債務返済能力: NATCOPHARMの負債は 営業キャッシュフロー によって 十分にカバー されています ( 326.4% )。
インタレストカバレッジ: NATCOPHARMの負債に対する 利息支払い は EBIT ( 97.5 x coverage) によって 十分にカバーされています。